16/02/2026
🧬 Stem cells & diabetes — where are we really?
A 2026 review in Diabetes & Metabolism looked at the major clinical trials investigating stem cell–based therapies for diabetes. This is a fast-paced field! 🚀
In summary: 🤓
✨ The goal: Restore insulin production or protect remaining beta cells. To move beyond lifelong insulin therapy. 🎯
🔬 Main approaches:
• Embryonic & induced pluripotent stem cells (iPSCs) → turned into insulin-producing cells and transplanted
• Mesenchymal stem cells (MSCs) → don’t make insulin, but may reduce inflammation and support beta cells
• Encapsulation devices → aim to protect transplanted cells from immune attack (without lifelong immunosuppression)
🚀 Big developments:
• Programs like Vertex’s VX-880 (zimislecel) have shown restored insulin production and major reductions in insulin needs in early trials.
• Some participants have achieved insulin independence (but most approaches still require immunosuppression).
• Autologous (derived from the person) stem cell strategies are emerging.
⚠️ Remaining challenges:
• Immune rejection
• Need for immunosuppression
• Long-term safety (tumor risk)
• Device durability & vascularization
• Scalability & cost
📌 Bottom line:
Stem cell therapy for diabetes is no longer science fiction. It’s clinically real, but still quite far from routine care. The next few years will be critical.
For those of us living with type 1 diabetes, this is one of the most closely watched frontiers in medicine. 👀